Prevalence of complications in children with chronic kidney disease according to KDOQI  by Wong, H. et al.
Prevalence of complications in children with chronic
kidney disease according to KDOQI
H Wong1, K Mylrea1, J Feber1, A Drukker2 and G Filler1
1Department of Pediatrics, Division of Nephrology, Children’s Hospital of Eastern Ontario, Ottawa, Ontario, Canada and 2Shaare Zedek
Medical Center, Jerusalem, Israel
The Kidney Disease Outcome and Quality Initiative (KDOQI)
Group recommended guidelines for the monitoring and
treatment of chronic kidney disease (CKD) in 2002. These
recommendations were based on the prevalence of known
complications as seen in adults. In children, the exact
prevalence of these complications is unknown. We therefore
conducted a cross-sectional study of 366 patients with CKD in
a single center to analyze the prevalence of these
complications across all stages of kidney disease. Patients
were categorized to their KDOQI stage of CKD according to
their estimated renal function as determined from serum
cystatin C. Fifty seven percent of patients had CKD stage 1,
29.0% stage 2, 10.4% stage 3 and 4.1% stages 4þ 5.
Uropathies (31%) were the most prevalent causes of CKD.
Glomerular disease accounted for 27%. The overall
prevalence of complications was as follows: hypertension
70.2%, anemia 36.6%, proteinuria 11.5%, and metabolic bone
disease 16.9%. Metabolic bone disease and anemia occurred
frequently, even with a glomerular filtration rate 460 ml/
min/1.73 m2. Growth failure (11.5%) was also common and is
not a component of the KDOQI guidelines for CKD in
children. The prevalence of all complications increased with
worsening stage of kidney disease (all P-values significant). In
summary, this study supports the KDOQI guidelines in
defining and staging CKD in children. This study also
highlights the differences in the causes and complications
that occur in CKD between adults and pediatrics. We
recommend modification of the KDOQI guidelines for
children to reflect the differences described in this paper.
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Recent publications by the Kidney Disease and Outcome
Quality Initiative (KDOQI) Group have suggested guidelines
for the treatment of patients with chronic kidney disease
(CKD).1 In 2003, these guidelines were reviewed and
recommended for the same use in children with CKD.2
Complications of CKD may include hyperkalemia, protein-
uria, hypertension, anemia, acidosis, and metabolic bone
disease.3,4 In addition to these complications, pediatric CKD
patients have problems such as growth failure and cognitive
impairment,5,6 which are not included in the KDOQI
guidelines. Few studies have reported the prevalence of these
abnormalities in childhood onset CKD.7
The aim of the study was to assess the prevalence of
complications that occurred in our children with CKD. We
hypothesized that there would be a child-specific pattern of
complications of CKD based on the differences in physiology
and underlying diagnosis.
RESULTS
Three hundred and sixty-six patients were included in this
study, 221 patients were male and the mean age was 9.975.1
years. The seven most common CKD diagnoses included
non-syndromic renal dysplasia (n¼ 47), autosomal-domi-
nant polycystic kidney disease (n¼ 29), renal scarring
(n¼ 28), renal transplant recipients (n¼ 25), posterior
urethral valves (n¼ 24), reflux nephropathy (n¼ 23), and
Alport’s disease (n¼ 20). Sixty-two different diagnoses
accounted for the remaining children with CKD. We
classified these diagnoses according to the following head-
ings: cystic (n¼ 47), tubular (n¼ 30), glomerular diseases
(n¼ 100), uropathies (n¼ 114), and renal hypoplasia or
dysplasia (n¼ 75). The distribution of patients according to
these headings and the CKD stages is listed in Table 1.
Overall, the prevalence of glomerular disease decreased and
the prevalence of tubular disease increased with increasing
stage of CKD (P¼ 0.01 and 0.0002). Glomerular disease
accounted for 27.0% of the overall causes of CKD compared
with uropathies, which accounted for 31.1% (Table 1).
The cystatin C (CysC)-based glomerular filtration rate
(GFR) was compared with 346 patients who had sufficient
information to calculate a Schwartz-based GFR, using the
published constants8 20% because of the measurement of
creatinine with an enzymatic method. The median Schwartz
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GFR (94.3) and median CysC GFR (93.6) were compared
with the Wilcoxon’s matched pairs test and we found no
statistical difference (P¼ 0.9855). Bland–Altman analysis of
the two methods for calculating GFR showed an overall bias
of 0.01% and s.d. of the bias of 28%. Surprisingly, these
results suggest good agreement between the two methods of
calculating GFR. The mean GFR of our renal transplant
patients was 69.5 ml/min/1.73 m2 (range 34.4–124.7). There
were six patients treated with dialysis: two with peritoneal
dialysis and four with hemodialysis. Fifteen patients less than
1 year of age with a mean age-corrected GFR of 88 ml/min/
1.73 m2 (range 24–151) were included in the study.
Anemia (using the KDOQI cutoff of a hemoglobin
o120 g/l) was present in 36.6% of the overall cohort. The
prevalence of anemia increased from 31% at stage 1 to 93.3%
at stages 4 and 5 (Po0.001). Treatment with either iron or
hormone therapy correlated closely with the stage of kidney
disease (both Po0.0001), whereas hemoglobin o120 g/l did
not correlate with the stage of kidney disease.
Hypertension, as expected, was the most common
complication to occur in CKD across all five stages
(70.2%). It is noteworthy that even in CKD stage 1, 63% of
patients had hypertension. Angiotensin-converting enzyme
inhibitors and/or angiotensin II type I receptor blockers were
used in 61.7%. These drugs were most often utilized in CKD
stage 3 with 76.3%, whereas only 66.6% of patients received
angiotensin II type I receptor blockers or angiotensin-
converting enzyme inhibitors in CKD stages 4 and 5. We
did not evaluate whether concerns about hyperkalemia may
have contributed to this lower percentage.
The prevalence of proteinuria (41 g/day) increased across
all stages of CKD (Po0.0001). This prevalence ranged
between 5.8% in stage 1 and 40% in stages 4þ 5. The overall
prevalence of proteinuria 41 g/day was 11.5%.
One-sixth (16.9%) of patients had metabolic bone disease.
Intact serum parathyroid hormone (PTH), treatment with
1,25-dihydroxy vitamin D, phosphate binders, and phosphate
dietary restrictions increased with severity of disease. The
prevalence of metabolic bone disease was as high as 15.09%
in stage 2 disease, 47.37% in stage 3, and 100% in stages 4
and 5 CKD. Interestingly, 6.28% of patients with CKD stage 1
also fit the criteria of metabolic bone disease.
Growth failure occurred in 11.5% of patients. The
prevalence of growth failure increased with increasing stage
of CKD (P¼ 0.0001). The overall use of growth hormone in
our patients was 3% and was highest in patients with CKD
stages 4 and 5 (20%).
The prevalence of hyperkalemia (overall 1.6%), acidosis
(overall 4.4%), and electrolyte wasting (5.7%) requiring
supplementation all increased with severity of disease.
Patients on dialysis were excluded from the analysis for
hyperkalemia. These results are summarized in Table 2 and
Figure 1.
DISCUSSION
This paper describes the prevalence of complications that
occur in children with CKD according to the stages proposed
by the KDOQI guidelines. These stages were based in part on
the increasing prevalence of abnormalities associated with
CKD in adults.9 KDOQI recommended the same definitions
and staging criteria for children with CKD older than 2 years
of age.2 However, application of these guidelines according to
CKD stage in children has never been validated. This paper
therefore represents the first attempt to describe the
Table 1 | Prevalence of CKD according to KDOQI stage of kidney disease and pathophysiological cause
Number Overall % % Stage 1 % Stage 2 % Stage 3 % Stages 4 and 5
Cystic 47 12.81 15.94 6.60 15.79 6.67
Tubular 30 8.17 3.38 14.15 10.53 26.67
Glomerular 100 27.25 33.33 18.87 23.68 13.33
Uropathy 114 31.06 34.30 30.19 26.32 6.67
Dysplastic 75 20.44 13.04 30.19 23.68 46.67
366
CKD, chronic kidney disease; KDOQI, Kidney Disease and Outcome Quality Initiative.
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Figure 1 | Prevalence of complications according to KDOQI stage
of CKD. The following complications were analyzed: hypertension,
anemia, proteinuria, growth failure, metabolic bone disease,
hyperkalemia, electrolyte wasting, and acidosis. Overall, the
prevalence of complications increased with declining kidney
function. In addition, the prevalence of anemia and metabolic
bone disease occurred earlier and higher in children than
previously reported in adults compared with hypertension which
occurred less frequently.
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prevalence of complications in children with CKD using the
KDOQI guidelines.
There are several important findings from this paper.
In our cohort, obstructive uropathy (30%) and glomerular
disease (27%) were the most common causes of CKD,
in contrast to adult patients in whom diabetic nephropathy
(36.9%) and hypertensive nephrosclerosis (24.2%) account
for the major causes of CKD in adults with end-stage
renal failure.10 In our advanced CKD stages, tubulopathies
and renal dysplasia prevailed. The predominance of
uropathy and dysplasias as the major causes of childhood
onset CKD has also been demonstrated by several previous
studies.11–13 In comparison, urological disorders account for
only 3% of the total end-stage renal disease population in
adults.14 This difference likely influenced the prevalence of
complications that occur in children when compared with
adults.
Similar to adult patients,15 common complications
included hypertension, anemia, bone disease, and protein-
uria. It is important to note that blood pressure is age-
dependent in children and that blood pressure z-scores have
to be reported rather than absolute blood pressure. This has
been recognized in the pediatric section of the updated
KDOQI guidelines.16 Blood pressure is not the only
age-dependent parameter. The KDOQI has just recently
recognized the age dependency of hemoglobin in their
updated guidelines for treatment of children and adolescents
on dialysis, as announced at the Annual Dialysis Conference,
San Francisco, 25–28 February 2006. These recommendations
have yet to be applied to CKD. It is therefore unclear whether
applying the KDOQI guidelines for the treatment of anemia
in CKD, over- or underestimates the true prevalence. We
recommend a more detailed analysis comparing age-depen-
dent pediatric reference ranges and KDOQI criteria for
anemia in CKD, before applying these guidelines in children.
Applying the KDOQI guidelines suggests a higher prevalence
of anemia in our cohort (31.25% in CKD 1 to 93.3% in CKD
4 and 5) when compared to adults (17% in CKD1 to 85% in
CKD.5,17 In comparison, North American Pediatric Renal
Transplant Cooperative Study analyzed complications of
CKD in children with a GFR o75 ml/min/1.73 m2. In a
cohort of 1725 patients, 30% had anemia as defined as a
hematocrit o30%. For a GFR o10, 62% of patients had
anemia, and for a GFR between 10 and 25 ml/min/1.73 m2,
48% of patients had anemia, and for a GFR of 25–50 ml/min/
1.73 m2, 25.7% of patients had anemia. Finally, for a GFR of
50–75 ml/min/1.73 m2, 13.1% had anemia.7 This study did
not combine therapeutic interventions and measured
abnormalities in their definition of anemia. This is the most
likely reason why the prevalence of anemia in our study
Table 2 | Prevalence of complications in children with CKD according to KDOQI stage of kidney disease
CKD1 CKD2 CKD3 CKD4 +5 P-value
Number of patients 207 106 38 15 —
% of total patients 56.6 29.0 10.4 4.1 —
Anemia (%) 31.25 28.57 65.8 93.3 o0.001
Treated with iron (%) 7.69 11.43 44.7 86.7 o0.0001
Treated with darbepoeitin (%) 0.5 8.6 23.7 86.7 o0.0001
Hgb o120 g/l (%) 27.9 20.95 39.5 40 0.282
Hypertension (%) 63.29 78.30 81.58 80.00 0.003
Patients on BP medications (%) 59.42 71.70 76.32 73.33 0.013
Patients on ACEi or ARB (%) 56.04 66.98 76.32 66.67 0.014
Patients on duo therapy (%) 14.01 16.98 34.21 20.00 0.02
Hypertension (42 s.d. systolic BP, %) 9.18 14.15 7.89 20.00 0.33
Proteinuria (%) 5.80 12.26 28.95 40.00 o0.0001
Bone disease (%) 6.28 15.09 47.37 100.00 o0.0001
Treated with PO4 binders (%) 1.45 2.83 13.16 60.00 o0.0001
Treated with Vit D analogs (%) 0.48 10.38 36.84 80.00 o0.0001
PO4 restriction (%) 0.48 0.94 7.89 13.33 o0.0001
iPTH 410 (%) 1.45 2.83 13.16 20.00 o0.0001
Growth failure (%) 6.76 13.21 18.42 46.67 0.0001
Height z-score (7 s.d.) 0.0571.25 0.4471.16 0.1671.4 1.0471.00 0.0003
Short stature (%) 5.31 9.43 10.53 13.33 0.08
Any treatment for growth (i.e. nutrition or growth hormone, %)) 3.38 4.72 15.79 40.00 o0.0001
Growth hormone therapy (%) 0.48 1.89 13.16 20.00 o0.0001
Hyperkalemia (%) 0.48 0.94 5.26 18.18 0.0001
Acidosis (%) 0.97 4.72 7.89 54.55 o0.0001
Electrolyte wasting (%) 3.38 7.55 10.53 13.33 0.015
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CKD, chronic kidney disease; Hgb, hemoglobin; iPTH, intact parathyroid
hormone; PO4, phosphate; s.d., standard deviation; short stature, height less than 2 s.d.; Vit D, vitamin D.
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(36.6%) was higher than in the North American Pediatric
Renal Transplant Cooperative Study database (30%).
Another important difference has to be pointed out for
bone disease. According to KDOQI, investigation for bone
disease in adults is recommended for a GFRo60 ml/min/m2.
However, our data suggest that applying these guidelines
overlooks a considerable proportion of children with bone
disease that would require treatment in patients with stage 2
CKD and even stage 1. Possible reasons for the considerable
prevalence of bone disease in early stages of CKD include
somatic growth, and phosphate wasting with tubular disease.
Growth failure was also common and is only referenced in
the KDOQI guidelines as an appendix to peritoneal dialysis,
hemodialysis and nutrition. Previous studies have not shown
a clear relationship with renal function and growth failure.3,18
In our own study, growth failure (including treatment and
height z-score o2 s.d.) occurred in 11.5% of the entire
population and worsened with CKD stage.
In some cases, the effect of therapy or lack of therapy was
suggested in the results. For example, mean height z-score did
not decrease stepwise with the stage of kidney disease.
Instead, there was a substantial decrease in stage 2, than an
improvement in stage 3 before again decreasing in stage
4þ 5. This pattern is repeated with systolic blood pressures
42 s.d. This may suggests insufficient monitoring or
intervention in stage 2 CKD and increased attention to the
abnormality in stage 3. The further worsening of abnorm-
alities in stage 4þ 5 CKD is consistent with worsening renal
disease. Although this pattern is not repeated in hemoglobin
o120 g/l, the effect of intervention may explain the
nonsignificant P-value observed in this outcome measure.
The fact that proteinuria does increase with worsening
stage of CKD despite a decline in the prevalence of
glomerular disease is consistent with other studies that
suggest proteinuria is related to the severity of kidney
disease.9 Caution, however, is suggested regarding the
interpretation of the 24 h urine protein tests in this study
owing to the low number of 24 h urine collections that were
available.
Several aspects of our study need to be highlighted. We
used CysC for the estimation of GFR19,20 instead of the
commonly used Schwartz GFR estimate. KDOQI recom-
mended the use of the Schwartz formula for children;
however, it recognized the limitations of using this estimate
of GFR in the absence of a more practical method.2 In
children, CysC bears many advantages over creatinine,
especially with regards to its independence of height and
muscle mass.19 A recent meta-analysis demonstrated a
superior diagnostic performance of CysC, especially in mildly
impaired GFR.16 For these reasons, we have consistently used
CysC as a surrogate marker of GFR since 2003. Secondly, to
our knowledge, no studies have previously described the rate
of abnormalities as they occur in children with CKD1 and
CKD2. Finally, our definitions for abnormalities accounted
for both measured abnormalities and the need for therapeu-
tic interventions. For some abnormalities, such as anemia
and bone disease, this approach likely provides a more
precise measurement. For other abnormalities, such as
hypertension and growth failure, this approach may artifi-
cially increase the prevalence. Certainly in the case of
hypertension, any use of antihypertensive medications was
considered as part of the definition. However, angiotensin-
converting enzyme inhibitors and angiotensin receptor
blockers were often employed in normotensive proteinuric
patients as renoprotective or antiproteinuric agents. This
would lead to an overestimation of the true prevalence of
hypertension. An additional limitation is implied by the fact
that age dependency was only considered for blood pressure
and height, whereas the KDOQI guidelines for anemia and
metabolic bone disease do not account for age dependencies.
In conclusion, the severity of complications increases with
severity of CKD similar to adult patients, thus supporting the
use of the KDOQI definitions and staging criteria in children.
However, this report also demonstrates that these criteria
need to be modified to properly address some of the issues
such as age-dependency of laboratory data and growth.
MATERIALS AND METHODS
The study was pre-approved by the hospital Research and Ethics
Board. Between July 2005 and September 2005, we reviewed all
outpatient nephrology clinic charts. Patients had to have at least one
visit in the calendar year 2005. Out of the 1679 patients, we included
those patients who met either of the KDOQI definitions for CKD
(Appendix A).1 Three physician investigators (HW, JF, GF)
individually reviewed the eligibility for inclusion and patients were
only included in the case of consensus.
Patients were divided into five groups according to the degree of
renal dysfunction based on the KDOQI cutoffs. GFR was
determined from the measured CysC concentration using the
formula published by Filler and Lepage.19 This formula was
validated against nuclear medicine GFR clearance studies
((99m)Tc-diethylenetriamine pentaacetic acid single-injection tech-
nique) and reads: log(GFR)¼ 1.962þ [1.123log(1/CysC)]. Since
2003, CysC determinations have routinely been employed in our
center. In infants less than 1 year of age, GFR was expressed as the
percentage of the measured GFR and reference data for that age.21
CKD stage I was interpreted to include patients at risk for the
deterioration of renal function or development of complications.
Accordingly, we excluded the following pediatric nephrology
patients with a GFR 490 ml/min/1.73 m2 and a low likelihood for
the development of renal failure: Essential hypertension, non-renal
hypertension, steroid-responsive nephrotic syndrome, single solitary
kidney, unilateral nephrectomy with normal contralateral renal
function, multicystic dysplastic kidney with normal function in
contralateral kidney, orthostatic proteinuria, benign familial hema-
turia, dysfunctional voiding, nocturnal enuresis, and recurrent
urinary tract infections without evidence of renal scarring. The most
common diagnoses that were excluded as follows: enuresis and
dysfunctional voiding (n¼ 506), non-renal hypertension (n¼ 180),
isolated hematuria (n¼ 161), and undifferentiated proteinuria
(n¼ 161). Examples of diagnoses that were included are: auto-
somal-dominant polycystic kidney disease, steroid resistant nephro-
tic syndrome, immunoglobulin A Nephropathy, Alport’s disease,
reflux nephropathy, renal scarring, renal dysplasia, and renal
transplant recipients with normal GFR.
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CKD2 consisted of patients with a GFR between 60–90 ml/min/
1.73 m2, CKD3 comprised of patients with a GFR between 30 and
60 ml/min/1.73 m2, CKD4 included patients with a GFR between
15–30 ml/min/1.73 m2, and CKD5 finally consisted of patients who
were either on dialysis or who had a GFR of o15 ml/min/1.73 m2.
As only six patients were on dialysis, CKD4 and CKD5 were
combined as a single group for the analysis.
Data collected from the charts included: demographic data,
current medication list, current dietary restrictions/supplementa-
tions, and electrolyte replacement, height, weight, and casual blood
pressure (second of two measurements performed 5 min apart), as
available from the last clinic visit in each patient. Laboratory
information included the most recent CysC, intact PTH, serum
potassium, ionized calcium, serum phosphate, serum bicarbonate,
hemoglobin, hematocrit, mean corpuscle volume, and 24 h urine
protein collection. Occasionally, not all laboratory results such as
PTH were obtained on the same day as the most recent CysC. We
included past results within a 3-month window.
The definition of the following uremic complications were used
for statistical analysis:
K Hypertension: Either any use of antihypertensive medica-
tions or last random systolic blood pressure greater than
2 s.d. above the normal mean.
K Anemia: Either any medical treatment for anemia (includ-
ing supplemental iron therapy or darbepoeitin alpha
therapy) or most recent hemoglobin less than 120 g/l.
K Metabolic bone disease: Either any medical therapy for bone
disease (including phosphate binders or vitamin D
analogues) or dietary phosphate restriction or most recent
intact PTH greater than 10 pmol/l.
K Growth: Either treatment with growth hormone therapy or
the use of hypercaloric formulas (420 kcal/oz in o2 year
old or 41 kcal/ml in 42 year old) or the use of
supplemental tube feeding or height less than 2 s.d. below
the mean.
K Hyperkalemia: Either any treatment with potassium
binders or potassium dietary restriction or most recent
serum potassium greater than 6.0 mmol/l
K Acidosis: Either any treatment to replace bicarbonate or
most recent venous bicarbonate of less than 20 mmol/l
K Proteinuria: Twenty-four hour urine protein collection
greater than 1 g/day
K Electrolyte wasting: use of either sodium, potassium, or
magnesium supplements.
Complete data were available for height, weight, blood pressure,
CysC, creatinine, potassium, and hemoglobin. In total, 10% of the
entire data set was missing. Twenty-four hour urine protein and
intact PTH had the highest percentage of missing data at 65.13 and
42.9%. This is largely owing to the fact that young children cannot
obtain 24-h urines, and PTH was not routinely measured with a
GFR 475 ml/min/1.73 m2. Three hundred and fifty-nine of 366
patients (98.1%) had data reflecting urinalysis performed at the time
of their last clinic visit. One hundred and fifty-one patients (41.3%)
had positive urine dipsticks of 0.3 g/l or more. Of these, 39 patients
(10.7%) had urinalysis 41 g/l. The semiquantitative urinary protein
determination with the dipstick cannot be considered a reliable
assessment of proteinuria. Only a fraction of patients had urinary
protein to creatinine ratio ordered, precluding this parameter from
the analysis. Darbepoietin was the only erythropoeitic agent used to
treat renal anemia. The decision to initiate therapy for the diagnosis
of non-iron-deficient renal anemia varied by the requirements of the
two provincial governments dividing our catchment area. All
patients with a hemoglobin o110 g/l and a GFR of o35 ml/min/
1.73 m2 would receive darbepoietin therapy.
Statistical analysis
Data taken at the last outpatient clinic visit were used to calculate
the point prevalence for each complication, both for the entire
group and than separately for each CKD stage. Comparison of
height and blood pressure (systolic and diastolic) were made using
the z-scores as calculated from the following published data.22,14 The
statistical package GraphPad Prism (Version 4.03, GraphPad Prism
Software for Science, San Diego, CA, USA) was used for statistical
analysis. Wherever possible, we used simple descriptive statistics
after assessing for normal distribution with the Pearson omnibus
test for continuous data. Parametric parameters were expressed as
mean71 s.d., and non-parametric data were expressed as median
and range. The w2 test for trends (categorical data) and analysis of
variance (continuous data) were used to compare CKD stages. No
adjustment was made for missing data.
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